INVESTOR ALERT: Kaplan Fox Announces Investigation Of Genocea Biosciences, Inc.

NEW YORK, Nov. 7, 2017

Class action litigation has been filed in the United States District Court for the District of Massachusetts against Genocea and certain Company executives on behalf of investors who purchased or otherwise acquired Genocea securities between May 5, 2017 and September 25, 2017, inclusive (the "Class"), alleging violations of the Securities Exchange Act of 1934.

On September 25, 2017 after the market closed, Genocea disclosed that it was halting spending and activities on GEN-003, its lead product candidate, and exploring strategic alternatives for the drug.  The Company also announced that it was cutting 40% of its workforce.

On September 26, 2017, the first trading day following the news, Genocea's share price fell $4.08 per share, or 76.5%, to close at $1.25 per share on September 26, 2017.

The complaint alleges that throughout the Class Period, the defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies.  Further, the complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that (i) the Company's finances were insufficient to support Phase 3 trials of GEN-003, (ii) accordingly, Genocea had overstated the prospects for GEN-003, and (iii) as a result of the foregoing, Genocea's public statements were materially false and misleading at all relevant times.

If you are a member of the proposed Class, you may move the court no later than January 2, 2018 to serve as a lead plaintiff for the purported class.  You need not seek to become a lead plaintiff in order to share in any possible recovery.  If you would like to discuss the complaint or our investigation, please contact us by emailing pmayer@kaplanfox.com or by calling 800-290-1952.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.